Abstract
The results of the previous study (Volchegorsky I.A., Vazhenin A.V., Alekseeva A.P., 2022) allow us to consider emoxypine, ethoxydol and mexidol as equally effective maintenance therapy means that improve the quality of life at the stage of postoperative radiation treatment of patients with uterine corpus cancer. In such a situation, the decision on the purchase of an optimal drug by a medical institution is closely related to the market price of the drug and the cost-effectiveness pharmacoeconomic indicator, which makes it possible to select a drug from the analyzed group based on the minimum cost of the "unit of effect". Objective: to conduct a comparative analysis of the cost of the "unit of effect" of emoxypine, ethoxydol and mexidol, used to improve the quality of life of women receiving radiation therapy af ter surgical treatment of uterine corpus cancer.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
